Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 108

1.

Enhancing safety of cytomegalovirus-based vaccine vectors by engaging host intrinsic immunity.

Marshall EE, Malouli D, Hansen SG, Gilbride RM, Hughes CM, Ventura AB, Ainslie E, Selseth AN, Ford JC, Burke D, Kreklywich CN, Womack J, Legasse AW, Axthelm MK, Kahl C, Streblow D, Edlefsen PT, Picker LJ, Früh K.

Sci Transl Med. 2019 Jul 17;11(501). pii: eaaw2603. doi: 10.1126/scitranslmed.aaw2603.

PMID:
31316006
2.

Contributions of the nurse's clinical practice to Primary Care.

Kahl C, Meirelles BHS, Cunha KSD, Bernardo MDS, Erdmann AL.

Rev Bras Enferm. 2019 Mar-Apr;72(2):354-359. doi: 10.1590/0034-7167-2018-0348. Epub 2019 Apr 18. English, Portuguese.

3.

Relevance of baseline carcinoembryonic antigen for first-line treatment against metastatic colorectal cancer with FOLFIRI plus cetuximab or bevacizumab (FIRE-3 trial).

Holch JW, Ricard I, Stintzing S, Fischer von Weikersthal L, Decker T, Kiani A, Vehling-Kaiser U, Heintges T, Kahl C, Kullmann F, Scheithauer W, Moehler M, Jelas I, Modest DP, Westphalen CB, von Einem JC, Michl M, Heinemann V.

Eur J Cancer. 2019 Jan;106:115-125. doi: 10.1016/j.ejca.2018.10.001. Epub 2018 Nov 27.

PMID:
30496943
4.

Referral and counter-referral: repercussions of coronary artery bypass graft in the perspective of Primary Care.

Kahl C, Cunha KSD, Lanzoni GMM, Higashi GDC, Erdmann AL, Baggio MA.

Rev Bras Enferm. 2018 Sep-Oct;71(5):2359-2366. doi: 10.1590/0034-7167-2016-0598. English, Portuguese.

5.

Myocardial revascularization: factors intervening in the reference and counter-reference in the hospital setting.

Cunha KSD, Kahl C, Koerich C, Lanzoni GMM, Erdmann AL, Meirelles BHS.

Rev Bras Enferm. 2018 Jul-Aug;71(4):1817-1824. doi: 10.1590/0034-7167-2017-0218. English, Portuguese.

6.

Care management of a patient with Devic's Disease in Primary Health Care.

Fabrizzio GC, Gonçalves Júnior E, Cunha KSD, Kahl C, Santos JLGD, Erdmann AL.

Rev Esc Enferm USP. 2018 Aug 6;52:e03345. doi: 10.1590/S1980-220X2017024603345. Portuguese, English.

7.

Actions and interactions in clinical nursing practice in Primary Health Care.

Kahl C, Meirelles BHS, Lanzoni GMM, Koerich C, Cunha KSD.

Rev Esc Enferm USP. 2018;52:e03327. doi: 10.1590/s1980-220x2017025503327. Epub 2018 May 24. English, Portuguese.

8.

Ultrafiltered recombinant AAV8 vector can be safely administered in vivo and efficiently transduces liver.

Kleven MD, Gomes MM, Wortham AM, Enns CA, Kahl CA.

PLoS One. 2018 Apr 5;13(4):e0194728. doi: 10.1371/journal.pone.0194728. eCollection 2018.

9.

Reduced Cell-Associated DNA and Improved Viral Control in Macaques following Passive Transfer of a Single Anti-V2 Monoclonal Antibody and Repeated Simian/Human Immunodeficiency Virus Challenges.

Hessell AJ, Shapiro MB, Powell R, Malherbe DC, McBurney SP, Pandey S, Cheever T, Sutton WF, Kahl C, Park B, Zolla-Pazner S, Haigwood NL.

J Virol. 2018 May 14;92(11). pii: e02198-17. doi: 10.1128/JVI.02198-17. Print 2018 Jun 1.

10.

PICCA study: panitumumab in combination with cisplatin/gemcitabine chemotherapy in KRAS wild-type patients with biliary cancer-a randomised biomarker-driven clinical phase II AIO study.

Vogel A, Kasper S, Bitzer M, Block A, Sinn M, Schulze-Bergkamen H, Moehler M, Pfarr N, Endris V, Goeppert B, Merx K, Schnoy E, Siveke JT, Michl P, Waldschmidt D, Kuhlmann J, Geissler M, Kahl C, Evenkamp R, Schmidt T, Kuhlmann A, Weichert W, Kubicka S.

Eur J Cancer. 2018 Mar;92:11-19. doi: 10.1016/j.ejca.2017.12.028. Epub 2018 Feb 3.

PMID:
29413685
11.

Anti-Müllerian hormone is a survival factor and promotes the growth of rhesus macaque preantral follicles during matrix-free culture.

Xu J, Xu F, Lawson MS, Tkachenko OY, Ting AY, Kahl CA, Park BS, Stouffer RR, Bishop CV.

Biol Reprod. 2018 Feb 1;98(2):197-207. doi: 10.1093/biolre/iox181.

12.

Exploring the effect of primary tumor sidedness on therapeutic efficacy across treatment lines in patients with metastatic colorectal cancer: analysis of FIRE-3 (AIOKRK0306).

Modest DP, Stintzing S, von Weikersthal LF, Decker T, Kiani A, Vehling-Kaiser U, Al-Batran SE, Heintges T, Kahl C, Seipelt G, Kullmann F, Scheithauer W, Moehler M, Holch JW, von Einem JC, Held S, Heinemann V.

Oncotarget. 2017 Nov 11;8(62):105749-105760. doi: 10.18632/oncotarget.22396. eCollection 2017 Dec 1.

13.
14.

Relevance of liver-limited disease in metastatic colorectal cancer: Subgroup findings of the FIRE-3/AIO KRK0306 trial.

Holch JW, Ricard I, Stintzing S, Fischer von Weikersthal L, Decker T, Kiani A, Vehling-Kaiser U, Al-Batran SE, Heintges T, Lerchenmüller C, Kahl C, Kullmann F, Scheithauer W, Scholz M, Müller S, Link H, Rost A, Höffkes HG, Moehler M, Lindig RU, Miller-Phillips L, Kirchner T, Jung A, von Einem JC, Modest DP, Heinemann V.

Int J Cancer. 2018 Mar 1;142(5):1047-1055. doi: 10.1002/ijc.31114. Epub 2017 Nov 7.

15.

University management: contributions for nurses who are faculty members and managers.

Cunha KSD, Kahl C, Koerich C, Santos JLGD, Lanzoni GMM, Erdmann AL.

Rev Bras Enferm. 2017 Sep-Oct;70(5):1069-1074. doi: 10.1590/0034-7167-2017-0068. English, Portuguese.

16.

Evaluation of survival across several treatment lines in metastatic colorectal cancer: Analysis of the FIRE-3 trial (AIO KRK0306).

Modest DP, Ricard I, Stintzing S, Fischer von Weikersthal L, Decker T, Kiani A, Vehling-Kaiser U, Al-Batran SE, Heintges T, Kahl C, Seipelt G, Kullmann F, Scheithauer W, Moehler M, Westphalen CB, Holch JW, von Einem JC, Held S, Heinemann V; for FIRE-3/AIOKRK0306-investigators.

Eur J Cancer. 2017 Oct;84:262-269. doi: 10.1016/j.ejca.2017.07.030. Epub 2017 Aug 23.

PMID:
28843184
17.

Impact of BRAF and RAS mutations on first-line efficacy of FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab: analysis of the FIRE-3 (AIO KRK-0306) study.

Stintzing S, Miller-Phillips L, Modest DP, Fischer von Weikersthal L, Decker T, Kiani A, Vehling-Kaiser U, Al-Batran SE, Heintges T, Kahl C, Seipelt G, Kullmann F, Stauch M, Scheithauer W, Held S, Moehler M, Jagenburg A, Kirchner T, Jung A, Heinemann V; FIRE-3 Investigators.

Eur J Cancer. 2017 Jul;79:50-60. doi: 10.1016/j.ejca.2017.03.023. Epub 2017 Apr 29.

PMID:
28463756
18.

Myocardial revascularization: factors intervening in the reference and counter-reference in Primary Health Care.

Cunha KS, Higashi GD, Erdmann AL, Kahl C, Koerich C, Meirelles BH.

Rev Esc Enferm USP. 2016 Nov-Dec;50(6):965-972. doi: 10.1590/S0080-623420160000700013. English, Portuguese.

19.

Relation of early tumor shrinkage (ETS) observed in first-line treatment to efficacy parameters of subsequent treatment in FIRE-3 (AIOKRK0306).

Modest DP, Stintzing S, Fischer von Weikersthal L, Decker T, Kiani A, Vehling-Kaiser U, Al-Batran SE, Heintges T, Lerchenmüller C, Kahl C, Seipelt G, Kullmann F, Scheithauer W, Kirchner T, Jung A, Stauch M, von Einem JC, Moehler M, Held S, Heinemann V; FIRE-3 study investigators.

Int J Cancer. 2017 Apr 15;140(8):1918-1925. doi: 10.1002/ijc.30592. Epub 2017 Feb 8.

20.

[Comprehensive implementation of interprofessional quality circles regarding early prevention of childhood disadvantage in Baden Württemberg (Germany)].

Siebolds M, Münzel B, Müller R, Häußermann S, Paul M, Kahl C.

Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2016 Oct;59(10):1310-4. doi: 10.1007/s00103-016-2427-3. German.

PMID:
27590248
21.

FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab for metastatic colorectal cancer (FIRE-3): a post-hoc analysis of tumour dynamics in the final RAS wild-type subgroup of this randomised open-label phase 3 trial.

Stintzing S, Modest DP, Rossius L, Lerch MM, von Weikersthal LF, Decker T, Kiani A, Vehling-Kaiser U, Al-Batran SE, Heintges T, Lerchenmüller C, Kahl C, Seipelt G, Kullmann F, Stauch M, Scheithauer W, Held S, Giessen-Jung C, Moehler M, Jagenburg A, Kirchner T, Jung A, Heinemann V; FIRE-3 investigators.

Lancet Oncol. 2016 Oct;17(10):1426-1434. doi: 10.1016/S1470-2045(16)30269-8. Epub 2016 Aug 27. Erratum in: Lancet Oncol. 2016 Oct;17 (10 ):e420. Erratum in: Lancet Oncol. 2016 Nov;17 (11):e479.

PMID:
27575024
22.

A Rapid, Cost-Effective Method to Prepare Recombinant Adeno-Associated Virus for Efficient Gene Transfer to the Developing Mouse Inner Ear.

Gomes MM, Wang L, Jiang H, Kahl CA, Brigande JV.

Methods Mol Biol. 2016;1427:43-57. doi: 10.1007/978-1-4939-3615-1_3.

PMID:
27259920
23.

[Pustular psoriasis].

Weisenseel P, Wilsmann-Theis D, Kahl C, Reich K, Mössner R.

Hautarzt. 2016 Jun;67(6):445-53. doi: 10.1007/s00105-016-3804-4. Review. German.

PMID:
27240667
24.

CEA response is associated with tumor response and survival in patients with KRAS exon 2 wild-type and extended RAS wild-type metastatic colorectal cancer receiving first-line FOLFIRI plus cetuximab or bevacizumab (FIRE-3 trial).

Michl M, Stintzing S, Fischer von Weikersthal L, Decker T, Kiani A, Vehling-Kaiser U, Al-Batran SE, Heintges T, Lerchenmueller C, Kahl C, Seipelt G, Kullmann F, Stauch M, Scheithauer W, Hielscher J, Scholz M, Mueller S, Lerch MM, Modest DP, Kirchner T, Jung A, Heinemann V; FIRE-3 Study Group.

Ann Oncol. 2016 Aug;27(8):1565-72. doi: 10.1093/annonc/mdw222. Epub 2016 May 27.

PMID:
27234640
25.

Early short-term treatment with neutralizing human monoclonal antibodies halts SHIV infection in infant macaques.

Hessell AJ, Jaworski JP, Epson E, Matsuda K, Pandey S, Kahl C, Reed J, Sutton WF, Hammond KB, Cheever TA, Barnette PT, Legasse AW, Planer S, Stanton JJ, Pegu A, Chen X, Wang K, Siess D, Burke D, Park BS, Axthelm MK, Lewis A, Hirsch VM, Graham BS, Mascola JR, Sacha JB, Haigwood NL.

Nat Med. 2016 Apr;22(4):362-8. doi: 10.1038/nm.4063. Epub 2016 Mar 21.

26.

Knockdown of Progesterone Receptor (PGR) in Macaque Granulosa Cells Disrupts Ovulation and Progesterone Production.

Bishop CV, Hennebold JD, Kahl CA, Stouffer RL.

Biol Reprod. 2016 May;94(5):109. doi: 10.1095/biolreprod.115.134981. Epub 2016 Mar 16.

27.

Long-term follow-up of the AML97 study for patients aged 60 years and above with acute myeloid leukaemia: a study of the East German Haematology and Oncology Study Group (OSHO).

Kahl C, Krahl R, Becker C, Al-Ali HK, Sayer HG, Schulze A, Herold M, Hänel M, Scholl S, Hochhaus A, Uharek L, Maschmeyer G, Haehling D, Junghanß C, Peter N, Kämpfe D, Kettner E, Heinicke T, Fischer T, Kreibich U, Wolf HH, Niederwieser D.

J Cancer Res Clin Oncol. 2016 Jan;142(1):305-15. doi: 10.1007/s00432-015-2045-8. Epub 2015 Sep 25.

PMID:
26407768
28.

Impact of Subsequent Therapies on Outcome of the FIRE-3/AIO KRK0306 Trial: First-Line Therapy With FOLFIRI Plus Cetuximab or Bevacizumab in Patients With KRAS Wild-Type Tumors in Metastatic Colorectal Cancer.

Modest DP, Stintzing S, von Weikersthal LF, Decker T, Kiani A, Vehling-Kaiser U, Al-Batran SE, Heintges T, Lerchenmüller C, Kahl C, Seipelt G, Kullmann F, Stauch M, Scheithauer W, Held S, Möhler M, Jung A, Kirchner T, Heinemann V.

J Clin Oncol. 2015 Nov 10;33(32):3718-26. doi: 10.1200/JCO.2015.61.2887. Epub 2015 Aug 10.

PMID:
26261259
29.

A retrospective review of diagnosis and treatment modalities of neuroendocrine tumors (excluding primary lung cancer) in 10 oncological institutions of the East German Study Group of Hematology and Oncology (OSHO), 2010-2012.

Maschmeyer G, Mügge LO, Kämpfe D, Kreibich U, Wilhelm S, Aßmann M, Schwarz M, Kahl C, Köhler S, Grobe N, Niederwieser D.

J Cancer Res Clin Oncol. 2015 Sep;141(9):1639-44. doi: 10.1007/s00432-015-1954-x. Epub 2015 Mar 15.

PMID:
25773126
30.

Full genome sequence analysis of a novel adenovirus of rhesus macaque origin indicates a new simian adenovirus type and species.

Malouli D, Howell GL, Legasse AW, Kahl C, Axthelm MK, Hansen SG, Früh K.

Virol Rep. 2014 Sep;3-4:18-29.

31.

Spatiotemporal dynamics of triglyceride storage in unilocular adipocytes.

Chu M, Sampath H, Cahana DY, Kahl CA, Somwar R, Cornea A, Roberts CT Jr, Varlamov O.

Mol Biol Cell. 2014 Dec 15;25(25):4096-105. doi: 10.1091/mbc.E14-06-1085. Epub 2014 Oct 8.

32.

FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial.

Heinemann V, von Weikersthal LF, Decker T, Kiani A, Vehling-Kaiser U, Al-Batran SE, Heintges T, Lerchenmüller C, Kahl C, Seipelt G, Kullmann F, Stauch M, Scheithauer W, Hielscher J, Scholz M, Müller S, Link H, Niederle N, Rost A, Höffkes HG, Moehler M, Lindig RU, Modest DP, Rossius L, Kirchner T, Jung A, Stintzing S.

Lancet Oncol. 2014 Sep;15(10):1065-75. doi: 10.1016/S1470-2045(14)70330-4. Epub 2014 Jul 31.

PMID:
25088940
33.

Conditioning with treosulfan and fludarabine for patients with refractory or relapsed non-Hodgkin lymphoma.

Schmitt M, Trenschel R, Sayer HG, Schneider C, Glass A, Hilgendorf I, Treschl A, Junghanss C, Borchert K, Koenigsmann M, Casper J, Beelen DW, Freund M, Kahl C.

Mol Clin Oncol. 2014 Sep;2(5):773-782. Epub 2014 Jun 2.

34.

Effects of vector backbone and pseudotype on lentiviral vector-mediated gene transfer: studies in infant ADA-deficient mice and rhesus monkeys.

Carbonaro Sarracino D, Tarantal AF, Lee CC, Martinez M, Jin X, Wang X, Hardee CL, Geiger S, Kahl CA, Kohn DB.

Mol Ther. 2014 Oct;22(10):1803-16. doi: 10.1038/mt.2014.88. Epub 2014 Jun 13.

35.

Diagnosis and antimicrobial therapy of lung infiltrates in febrile neutropenic patients (allogeneic SCT excluded): updated guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO).

Maschmeyer G, Carratalà J, Buchheidt D, Hamprecht A, Heussel CP, Kahl C, Lorenz J, Neumann S, Rieger C, Ruhnke M, Salwender H, Schmidt-Hieber M, Azoulay E; Infectious Diseases Working Party of the German Society of Hematology and Medical Oncology.

Ann Oncol. 2015 Jan;26(1):21-33. doi: 10.1093/annonc/mdu192. Epub 2014 May 15.

36.

Molecularly tagged simian immunodeficiency virus SIVmac239 synthetic swarm for tracking independent infection events.

Del Prete GQ, Park H, Fennessey CM, Reid C, Lipkey L, Newman L, Oswald K, Kahl C, Piatak M Jr, Quiñones OA, Alvord WG, Smedley J, Estes JD, Lifson JD, Picker LJ, Keele BF.

J Virol. 2014 Jul;88(14):8077-90. doi: 10.1128/JVI.01026-14. Epub 2014 May 7.

37.

Cytomegalovirus pp65 limits dissemination but is dispensable for persistence.

Malouli D, Hansen SG, Nakayasu ES, Marshall EE, Hughes CM, Ventura AB, Gilbride RM, Lewis MS, Xu G, Kreklywich C, Whizin N, Fischer M, Legasse AW, Viswanathan K, Siess D, Camp DG 2nd, Axthelm MK, Kahl C, DeFilippis VR, Smith RD, Streblow DN, Picker LJ, Früh K.

J Clin Invest. 2014 May;124(5):1928-44. Epub 2014 Apr 1.

38.

Prophylaxis of infectious complications with colony-stimulating factors in adult cancer patients undergoing chemotherapy-evidence-based guidelines from the Infectious Diseases Working Party AGIHO of the German Society for Haematology and Medical Oncology (DGHO).

Vehreschild JJ, Böhme A, Cornely OA, Kahl C, Karthaus M, Kreuzer KA, Maschmeyer G, Mousset S, Ossendorf V, Penack O, Vehreschild MJ, Bohlius J; Infectious Diseases Working Party of the Society for Haematology and Medical Oncology.

Ann Oncol. 2014 Sep;25(9):1709-18. doi: 10.1093/annonc/mdu035. Epub 2014 Mar 14.

PMID:
24631945
39.

Therapy of mRCC beyond mTOR-inhibition in clinical practice: results of a retrospective analysis.

Maute L, Grünwald V, Weikert S, Kube U, Gauler T, Kahl C, Burkholder I, Bergmann L.

J Cancer Res Clin Oncol. 2014 May;140(5):823-7. doi: 10.1007/s00432-014-1610-x. Epub 2014 Feb 21.

PMID:
24556802
40.

Risk-adapted, treosulfan-based therapy with auto- and allo-SCT for relapsed/refractory aggressive NHL: a prospective phase-II trial.

Koenigsmann M, Casper J, Kahl C, Basara N, Sayer HG, Behre G, Theurich S, Christopeit M, Mohren M, Reichle A, Metzner B, Ganser A, Stadler M, Uharek L, Balleisen L, Hinke A, Hinke R, Niederwieser D.

Bone Marrow Transplant. 2014 Mar;49(3):410-5. doi: 10.1038/bmt.2013.199. Epub 2013 Dec 23.

PMID:
24362366
41.

[Mission paper for the further development of the curriculum "Evidence-based Medicine" by the German Medical Association and the German Network Evidence-based Medicine].

Siebolds M, Albrecht M, Kahl C, Langer G, Lühmann D, Pralle KH, Schwalbe O, Steckelberg A, Strametz R, Weingart O, Weberschock T.

Z Evid Fortbild Qual Gesundhwes. 2013;107(1):70-3. doi: 10.1016/j.zefq.2012.12.021. Epub 2013 Jan 16. German. No abstract available.

PMID:
23415346
42.

Toxic epidermal necrolysis related to Cisplatin and pemetrexed for metastatic non-small cell lung cancer.

Scheinpflug K, Menzel C, Koch A, Kahl C, Achenbach HJ.

Onkologie. 2012;35(10):600-3. doi: 10.1159/000342671. Epub 2012 Sep 18.

PMID:
23038233
43.

Chronic graft versus host disease but not the intensity of conditioning has impact on survival after allogeneic hematopoietic stem cell transplantation for advanced hematological diseases.

Hilgendorf I, Wolff D, Nogai A, Kundt G, Hahn J, Holler E, Uharek L, Junghanss C, Leithäuser M, Thiel E, Freund M, Kahl C.

Onkologie. 2012;35(9):487-92. Epub 2012 Aug 13.

PMID:
23007145
44.

Fludarabine and cyclophosphamide in combination with alemtuzumab in patients with primary high-risk, relapsed or refractory chronic lymphocytic leukemia.

Elter T, James R, Busch R, Winkler D, Ritgen M, Böttcher S, Kahl C, Gassmann W, Stauch M, Hasan I, Staib P, Fischer K, Fink AM, Bahlo J, Bühler A, Döhner H, Wendtner CM, Stilgenbauer S, Engert A, Hallek M.

Leukemia. 2012 Dec;26(12):2549-52. doi: 10.1038/leu.2012.129. Epub 2012 May 15. No abstract available.

PMID:
22584787
45.

[Nail psoriasis--an ignored disorder. Pathogenesis, diagnosis and therapy].

Kahl C, Hansen B, Reich K.

Hautarzt. 2012 Mar;63(3):184-91. doi: 10.1007/s00105-011-2228-4. Review. German.

PMID:
22382303
46.

Nonmyeloablative conditioning regimen to increase engraftment of gene-modified hematopoietic stem cells in young rhesus monkeys.

Tarantal AF, Giannoni F, Lee CC, Wherley J, Sumiyoshi T, Martinez M, Kahl CA, Elashoff D, Louie SG, Kohn DB.

Mol Ther. 2012 May;20(5):1033-45. doi: 10.1038/mt.2011.312. Epub 2012 Jan 31.

47.

Early versus late administration of pegfilgrastim after high-dose chemotherapy and autologous hematopoietic stem cell transplantation.

Kahl C, Sayer HG, Hinke A, Freund M, Casper J.

J Cancer Res Clin Oncol. 2012 Mar;138(3):513-7. doi: 10.1007/s00432-011-1116-8. Epub 2011 Dec 25.

PMID:
22198675
48.

[Recurrent hypoglycemia and a large intraabdominal tumor in a 61-year-old woman].

Kahl C, Jost K, Knauerhase A, Leithäuser M, Freund M, Bunke D, Rothacker D, Hampel R.

Dtsch Med Wochenschr. 2011 Dec;136(49):2542-6. doi: 10.1055/s-0031-1292841. Epub 2011 Nov 30. German.

PMID:
22131074
49.

Posterior reversible encephalopathy syndrome (PRES): an unusual primary manifestation of a diffuse large B-cell lymphoma.

Patejdl R, Borchert K, Pagumbke H, Benecke R, Grossmann A, Prall F, Kahl C, Freund M, Schmitt M, Walter U.

Clin Neurol Neurosurg. 2011 Nov;113(9):819-21. doi: 10.1016/j.clineuro.2011.08.018. Epub 2011 Sep 15. No abstract available.

PMID:
21924823
50.

Aircraft noise and quality of life around Frankfurt Airport.

Schreckenberg D, Meis M, Kahl C, Peschel C, Eikmann T.

Int J Environ Res Public Health. 2010 Sep;7(9):3382-405. doi: 10.3390/ijerph7093382. Epub 2010 Aug 31.

Supplemental Content

Support Center